Selecta Biosciences Announces $70 Million Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
AskBio Licenses Rights to Selecta Biosciences' (SELB) ImmTOR Immune Tolerance Platform for Treatment of Pompe Disease
December 19, 2019 8:26 AM ESTSelecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced that the companies have entered into a license agreement. Under the terms of... More

